Loading
Loading…
Loading…
131 results • Recent activity
Tungsten Inert Gas (TIG) Welding Equipment as per IS 9604:1994 (Q2)
Stationary Valve Regulated Lead Acid Batteries (V3) Conforming To IS 15549 (Q3)
FPGA based integrated Development Environment with model composer, Integrated RF SoC development module, Embedded MP SoC development module
Nitrile Coated/Nitrile Hand Gloves (V2) (Q3) MSE Relaxation for Years Of Experience and Turnover Yes | Complete Startup Relaxation for Years Of Experience and Turnover Yes | Complete Minimum number of bids required to disable automatic bid extension 3, -- Number of days for which Bid would be auto -- extended 7 Number of Auto Extension count 1 Bid to RA enabled Yes RA Qualification Rule H1-Highest Priced Bid Elimination Type of Bid Two Packet Bid Time allowed for Technical Clarifications during technical evaluation 2 Days Bid Number : GEM/2025/B/7018796 Dated : 18-12-2025 Bid Document 1/6 ( )/Inspection Required (By Empanelled Inspection Authority/Agencies pre-registered with GeM) No Evaluation Method Total value wise evaluation Arbitration Clause No Mediation Clause No Bid Details EMD Detail Required No ePBG Detail Required No
Household Refrigerating Appliances as per IS 17550 (Q2) MSE Relaxation for Years Of Experience and Turnover Yes | Complete Startup Relaxation for Years Of Experience and Turnover Yes | Complete Minimum number of bids required to disable automatic bid extension 3, -- Number of days for which Bid would be auto -- extended 7 Number of Auto Extension count 1 Bid to RA enabled Yes RA Qualification Rule H1-Highest Priced Bid Elimination Type of Bid Two Packet Bid Time allowed for Technical Clarifications during technical evaluation 2 Days Bid Number : GEM/2025/B/7007117 Dated : 17-12-2025 Bid Document 1/7 ( )/Inspection Required (By Empanelled Inspection Authority/Agencies pre-registered with GeM) No Evaluation Method Total value wise evaluation Arbitration Clause No Mediation Clause No Bid Details EMD Detail Required No ePBG Detail Required No
Phase-I Development of antisera in mice (5-6 mice/antigen), Phase-II Hybridoma generation via cell fusion and subsequent screening for monoclonal antibody produ, Phase-III Sub- cloning, screening and isotyping of three distinct clones specific to each antigen (0, Phase-IV Large scale productin and purification of monoclonal antibodies from the confirmed positive